Cargando…

Cardiotoxicity of Anticancer Therapeutics

As cancer therapeutics continues to improve and progress, the adverse side effects associated with anticancer treatments have also attracted more attention and have become extensively explored. Consequently, the importance of posttreatment follow-ups is becoming increasingly relevant to the discussi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Jerry, Chen, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810267/
https://www.ncbi.nlm.nih.gov/pubmed/29473044
http://dx.doi.org/10.3389/fcvm.2018.00009
_version_ 1783299722904076288
author Dong, Jerry
Chen, Hong
author_facet Dong, Jerry
Chen, Hong
author_sort Dong, Jerry
collection PubMed
description As cancer therapeutics continues to improve and progress, the adverse side effects associated with anticancer treatments have also attracted more attention and have become extensively explored. Consequently, the importance of posttreatment follow-ups is becoming increasingly relevant to the discussion. Contemporary treatment methods, such as tyrosine kinase inhibitors, anthracycline chemotherapy, and immunotherapy regimens are effective in treating different modalities of cancers; however, these reagents act through interference with DNA replication or prevent DNA repair, causing endothelial dysfunction, generating reactive oxygen species, or eliciting non-specific immune responses. Therefore, cardiotoxic effects, such as hypertension, heart failure, and left ventricular dysfunction, arise posttreatment. Rising awareness of cardiovascular complications has led to meticulous attention for the evolution of treatment strategies and carefully monitoring between enhanced treatment effectiveness and minimization of adverse toxicity to the cardiovasculature, in which psychological assessments, early detection methods such as biomarkers, magnetic resonance imaging, and various drugs to reverse the damage from cardiotoxic events are more prevalent and their emphasis has increased tremendously. Fully understanding the mechanisms by which the risk factors action for various patients undergoing cancer treatment is also becoming more prevalent in preventing cardiotoxicity down the line.
format Online
Article
Text
id pubmed-5810267
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58102672018-02-22 Cardiotoxicity of Anticancer Therapeutics Dong, Jerry Chen, Hong Front Cardiovasc Med Cardiovascular Medicine As cancer therapeutics continues to improve and progress, the adverse side effects associated with anticancer treatments have also attracted more attention and have become extensively explored. Consequently, the importance of posttreatment follow-ups is becoming increasingly relevant to the discussion. Contemporary treatment methods, such as tyrosine kinase inhibitors, anthracycline chemotherapy, and immunotherapy regimens are effective in treating different modalities of cancers; however, these reagents act through interference with DNA replication or prevent DNA repair, causing endothelial dysfunction, generating reactive oxygen species, or eliciting non-specific immune responses. Therefore, cardiotoxic effects, such as hypertension, heart failure, and left ventricular dysfunction, arise posttreatment. Rising awareness of cardiovascular complications has led to meticulous attention for the evolution of treatment strategies and carefully monitoring between enhanced treatment effectiveness and minimization of adverse toxicity to the cardiovasculature, in which psychological assessments, early detection methods such as biomarkers, magnetic resonance imaging, and various drugs to reverse the damage from cardiotoxic events are more prevalent and their emphasis has increased tremendously. Fully understanding the mechanisms by which the risk factors action for various patients undergoing cancer treatment is also becoming more prevalent in preventing cardiotoxicity down the line. Frontiers Media S.A. 2018-02-07 /pmc/articles/PMC5810267/ /pubmed/29473044 http://dx.doi.org/10.3389/fcvm.2018.00009 Text en Copyright © 2018 Dong and Chen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Dong, Jerry
Chen, Hong
Cardiotoxicity of Anticancer Therapeutics
title Cardiotoxicity of Anticancer Therapeutics
title_full Cardiotoxicity of Anticancer Therapeutics
title_fullStr Cardiotoxicity of Anticancer Therapeutics
title_full_unstemmed Cardiotoxicity of Anticancer Therapeutics
title_short Cardiotoxicity of Anticancer Therapeutics
title_sort cardiotoxicity of anticancer therapeutics
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810267/
https://www.ncbi.nlm.nih.gov/pubmed/29473044
http://dx.doi.org/10.3389/fcvm.2018.00009
work_keys_str_mv AT dongjerry cardiotoxicityofanticancertherapeutics
AT chenhong cardiotoxicityofanticancertherapeutics